You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR ONIVYDE

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for onivyde

Subscribe to access the full database, or Subscribe
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02231723 ↗	A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer	Completed	Boston Biomedical, Inc	Phase 1	2014-08-01	This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin.
NCT02231723 ↗	A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer	Completed	Sumitomo Dainippon Pharma Oncology, Inc	Phase 1	2014-08-01	This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin.
NCT02631733 ↗	Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors	Active, not recruiting	National Cancer Institute (NCI)	Phase 1	2016-07-15	This phase I trial studies the side effects and best dose of veliparib when given together with liposomal irinotecan in treating patients with solid tumors. Liposomal irinotecan and veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
NCT02785068 ↗	Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer	Withdrawn	Merrimack Pharmaceuticals	Phase 1/Phase 2	2016-07-01	A phase 1b/2a study evaluating the combination of MM-151 + nal-IRI + 5-FU + Leucovorin in RAS/RAF wild-type Metastatic Colorectal Cancer.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for onivyde

Condition Name

Chart
Table

Condition Name for onivyde
Intervention	Trials
Metastatic Pancreatic Adenocarcinoma	7
Pancreatic Cancer	4
Pancreatic Adenocarcinoma	3
Colorectal Cancer	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for onivyde
Intervention	Trials
Pancreatic Neoplasms	15
Adenocarcinoma	13
Carcinoma	8
Neoplasms	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for onivyde

Trials by Country

Map
Table

Trials by Country for onivyde
Location	Trials
United States	101
Korea, Republic of	5
Taiwan	5
Spain	4
Canada	4
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for onivyde
Location	Trials
Washington	7
Arizona	7
California	6
Florida	6
New York	6
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for onivyde

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for onivyde
Clinical Trial Phase	Trials
Phase 3	1
Phase 2/Phase 3	2
Phase 2	12
[disabled in preview]	9
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for onivyde
Clinical Trial Phase	Trials
Recruiting	12
Not yet recruiting	9
Active, not recruiting	9
[disabled in preview]	3
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for onivyde

Sponsor Name

Chart
Table

Sponsor Name for onivyde
Sponsor	Trials
Ipsen	9
National Cancer Institute (NCI)	6
China Medical University Hospital	2
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for onivyde
Sponsor	Trials
Other	42
Industry	28
NIH	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.